Literature DB >> 25099228

Technical standards for hepatitis B virus X protein (HBx) research.

Betty L Slagle1, Ourania M Andrisani, Michael J Bouchard, Caroline G L Lee, J-H James Ou, Aleem Siddiqui.   

Abstract

Chronic infection with hepatitis B virus (HBV) is a risk factor for developing hepatocellular carcinoma (HCC). The life cycle of HBV is complex and has been difficult to study because HBV does not infect cultured cells. The HBV regulatory X protein (HBx) controls the level of HBV replication and possesses an HCC cofactor role. Attempts to understand the mechanism(s) that underlie HBx effects on HBV replication and HBV-associated carcinogenesis have led to many reported HBx activities that are likely influenced by the assays used. This review summarizes experimental systems commonly used to study HBx functions, describes limitations of these experimental systems that should be considered, and suggests approaches for ensuring the biological relevance of HBx studies.
© 2014 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25099228      PMCID: PMC4320676          DOI: 10.1002/hep.27360

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  48 in total

Review 1.  The enigmatic X gene of hepatitis B virus.

Authors:  Michael J Bouchard; Robert J Schneider
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

2.  Differential immediate early gene expression in conditional hepatitis B virus pX-transforming versus nontransforming hepatocyte cell lines.

Authors:  C Tarn; M L Bilodeau; R L Hullinger; O M Andrisani
Journal:  J Biol Chem       Date:  1999-01-22       Impact factor: 5.157

3.  Cloning and characterization of a novel hepatitis B virus x binding protein that inhibits viral replication.

Authors:  M Melegari; P P Scaglioni; J R Wands
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

4.  Expression of mutated hepatitis B virus X genes in human hepatocellular carcinomas.

Authors:  K Poussin; H Dienes; H Sirma; S Urban; M Beaugrand; D Franco; P Schirmacher; C Bréchot; P Paterlini Bréchot
Journal:  Int J Cancer       Date:  1999-02-09       Impact factor: 7.396

5.  Proteins ZNF198 and SUZ12 are down-regulated in hepatitis B virus (HBV) X protein-mediated hepatocyte transformation and in HBV replication.

Authors:  Wen-Horng Wang; Leo L Studach; Ourania M Andrisani
Journal:  Hepatology       Date:  2011-04       Impact factor: 17.425

6.  Hepatitis B virus DNA replication is coordinated by core protein serine phosphorylation and HBx expression.

Authors:  Margherita Melegari; Sarah K Wolf; Robert J Schneider
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

7.  Hepatitis B virus X mutants, present in hepatocellular carcinoma tissue abrogate both the antiproliferative and transactivation effects of HBx.

Authors:  H Sirma; C Giannini; K Poussin; P Paterlini; D Kremsdorf; C Bréchot
Journal:  Oncogene       Date:  1999-08-26       Impact factor: 9.867

8.  Hepatitis B virus X protein stimulates viral genome replication via a DDB1-dependent pathway distinct from that leading to cell death.

Authors:  Olivier Leupin; Séverine Bontron; Céline Schaeffer; Michel Strubin
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

9.  Enhancement of hepatitis B virus replication by the regulatory X protein in vitro and in vivo.

Authors:  Victor V Keasler; Amanda J Hodgson; Charles R Madden; Betty L Slagle
Journal:  J Virol       Date:  2006-12-20       Impact factor: 5.103

10.  Hepatitis B virus promotes hepatocarcinogenesis in transgenic mice.

Authors:  Yanyan Zheng; Wen-ling Chen; Stan G Louie; T S Benedict Yen; Jing-hsiung James Ou
Journal:  Hepatology       Date:  2007-01       Impact factor: 17.425

View more
  34 in total

1.  Hepatitis B virus molecular biology and pathogenesis.

Authors:  R Jason Lamontagne; Sumedha Bagga; Michael J Bouchard
Journal:  Hepatoma Res       Date:  2016-07-01

2.  Hepatitis B Virus X Protein Induces SATB1 Expression Through Activation of ERK and p38MAPK Pathways to Suppress Anoikis.

Authors:  Wei Tu; Jin Gong; Dean Tian; Zhijun Wang
Journal:  Dig Dis Sci       Date:  2019-05-30       Impact factor: 3.199

Review 3.  Overview of hepatitis B viral replication and genetic variability.

Authors:  Shuping Tong; Peter Revill
Journal:  J Hepatol       Date:  2016-04       Impact factor: 25.083

4.  Hepatitis B Virus Deregulates the Cell Cycle To Promote Viral Replication and a Premalignant Phenotype.

Authors:  Yuchen Xia; Xiaoming Cheng; Yao Li; Kristin Valdez; Weiping Chen; T Jake Liang
Journal:  J Virol       Date:  2018-09-12       Impact factor: 5.103

5.  Farnesoid X receptor ablation sensitizes mice to hepatitis b virus X protein-induced hepatocarcinogenesis.

Authors:  Yongdong Niu; Meishu Xu; Betty L Slagle; Haihua Huang; Song Li; Grace L Guo; Ganggang Shi; Wenxin Qin; Wen Xie
Journal:  Hepatology       Date:  2017-01-19       Impact factor: 17.425

6.  Hepatitis B virus X protein enhances Myc stability by inhibiting SCF(Skp2) ubiquitin E3 ligase-mediated Myc ubiquitination and contributes to oncogenesis.

Authors:  S Lee; W Kim; C Ko; W-S Ryu
Journal:  Oncogene       Date:  2015-07-13       Impact factor: 9.867

Review 7.  Revisiting Hepatitis B Virus: Challenges of Curative Therapies.

Authors:  Jianming Hu; Ulrike Protzer; Aleem Siddiqui
Journal:  J Virol       Date:  2019-09-30       Impact factor: 5.103

Review 8.  Role of HBx in hepatitis B virus persistence and its therapeutic implications.

Authors:  Betty L Slagle; Michael J Bouchard
Journal:  Curr Opin Virol       Date:  2018-02-20       Impact factor: 7.090

Review 9.  Contributions of transgenic mouse studies on the research of hepatitis B virus and hepatitis C virus-induced hepatocarcinogenesis.

Authors:  Shogo Ohkoshi; Haruka Hirono; Kazuhiko Watanabe; Katsuhiko Hasegawa; Masahiko Yano
Journal:  World J Hepatol       Date:  2015-12-08

Review 10.  Genomics of Viral Hepatitis-Associated Liver Tumors.

Authors:  Camille Péneau; Jessica Zucman-Rossi; Jean-Charles Nault
Journal:  J Clin Med       Date:  2021-04-22       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.